CompletedNot Applicable

Efficacy of a VR Paradigm to Reduce Fear of Heights in a Clinical and Subclinical Population With Fear of Heights

Switzerland80 participantsStarted 2018-10-16

Plain-language summary

Investigation of the effectiveness and acceptability and usability of a VR height exposure App in individuals with fear of heights.

Who can participate

Age range18 Years – 60 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Clinical fear of heights (DSM-V) or subclinical fear of heights (fulfilment of DSM-C criteria A-E and G, but not F: distress/impairment) * Physically healthy * Aged between 18-60 * Fluent in German Exclusion Criteria: * Depression (BDI-II \> 8) * Suicidal ideation (BDI-II item 9 \> 0) * Concurrent psychotherapy or pharmacotherapy * Previous therapy for height phobia * Parallel participation in another study * Pregnancy (will be excluded with a pregnancy test during screening) * Chronic medication intake (except oral contraceptives) * Alcohol and medication intake before visit (less than 12 h) * Cannabis or other psychoactive substances (including benzodiazepines) intake before visit (less than 5 days) * Sleep-inducing drugs (incl. antihistamines) intake before visit (less than five days) * Restricted 3D sight

What they're measuring

Performance Behavioural Avoidance Test (BAT) in vivo

Timeframe: study phase 1: on study day within 1h after VR exposure, study phase 2: 3-5 weeks after completion of home training

Trial details

NCT IDNCT04003753

SponsorProf. Dominique de Quervain, MD

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2019-05-24

View on ClinicalTrials.gov More Fear of Heights trials